Welcome to our dedicated page for Scienture Holdings SEC filings (Ticker: SCNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
R&D milestones, FDA language, and detailed patient-service revenue make Scienture Holdings’ filings dense even for seasoned analysts. Tracking when executives file Form 4s just days before material 8-K announcements can feel like piecing together clinical trial data and accounting footnotes at the same time.
Stock Titan solves that problem. Our AI converts every Scienture Holdings quarterly earnings report 10-Q filing, annual report 10-K simplified summary, and Scienture Holdings 8-K material events explained into plain-English takeaways you can read in minutes. Need Scienture Holdings insider trading Form 4 transactions or Scienture Holdings Form 4 insider transactions real-time? They appear instantly, alongside AI-highlighted context such as upcoming drug approval dates. We also surface the numbers you search for most—R&D spend, specialty-drug margins, and reimbursement trends—so understanding Scienture Holdings SEC documents with AI becomes effortless.
Whether you’re reviewing a Scienture Holdings proxy statement executive compensation before voting, scanning a Scienture Holdings earnings report filing analysis for segment growth, or setting alerts for Scienture Holdings executive stock transactions Form 4, you’ll find the complete archive here, updated the moment EDGAR posts. No more page-by-page hunts: just clear answers to "Scienture Holdings SEC filings explained simply" and a streamlined view of compliance data investors actually use.
Soluna Holdings, Inc. (Nasdaq: SLNH / SLNHP) filed a Form 8-K under Item 8.01 (Other Events). The Board of Directors set August 18, 2025 as the date of the Company’s 2025 Annual Meeting of Stockholders and designated June 30, 2025 as the record date for determining shareholders entitled to notice of, and to vote at, the meeting. Because the new meeting date is more than 30 days later than last year’s meeting, the Company has reset the Rule 14a-8 deadline for shareholder proposals: submissions must be received by the Corporate Secretary no later than July 15, 2025 to be eligible for inclusion in the proxy statement. Proposals must also satisfy Nevada law, SEC regulations, and the Company’s Bylaws. The specific time and location of the meeting will be disclosed in the forthcoming proxy statement.
No financial results, transactions, or strategic changes were disclosed; the filing is limited to scheduling and procedural matters.
FAQ
What is the current stock price of Scienture Holdings (SCNX)?
What is the market cap of Scienture Holdings (SCNX)?
What is the core business of Scienture Holdings, Inc.?
How does the company generate revenue?
What distinguishes Scienture Holdings in the healthcare market?
How does Scienture address unmet market needs?
What role does patient engagement play in the company’s operations?
In what ways does the company integrate clinical insights with its offerings?
How does Scienture maintain a competitive edge?
What areas of the healthcare system does Scienture primarily serve?
